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Abstract
Background: Investigations on the effects of malaria infection on cancer mortality are limited except for the incidence
of Burkitt’s lymphoma (BL) in African children. Our previous murine lung cancer model study demonstrated that
malaria infection significantly inhibited tumor growth and prolonged the life span of tumor-bearing mice. This study
aims to assess the possible associations between malaria incidence and human cancer mortality.
Methods: We compiled data on worldwide malaria incidence and age-standardized mortality related to 30 types of
cancer in 56 countries for the period 1955–2008, and analyzed their longitudinal correlations by a generalized additive
mixed model (GAMM), adjusted for a nonlinear year effect and potential confounders such as country’s income levels,
life expectancies and geographical locations.
Results: Malaria incidence was negatively correlated with all-cause cancer mortality, yielding regression coefficients
(log scale) of −0.020 (95%CI: −0.027,-0.014) for men (P < 0.001) and-0.020 (95%CI: −0.025,-0.014) for women (P < 0.001).
Among the 29 individual types of cancer studied, malaria incidence was negatively correlated with colorectum and
anus (men and women), colon (men and women), lung (men), stomach (men), and breast (women) cancer.
Conclusions: Our analysis revealed a possible inverse association between malaria incidence and the mortalities
of all-cause and some types of solid cancers, which is opposite to the known effect of malaria on the
pathogenesis of Burkitt’s lymphoma. Activation of the whole immune system, inhibition of tumor angiogenesis
by Plasmodium infection may partially explain why endemic malaria might reduce cancer mortality at the
population level.
Keywords: Malaria incidence, Cancer mortality, Generalized additive mixed model (GAMM), Epidemiological data,
Regression analysis
Background
Some parasites have been implicated as risk factors for
certain cancers, including Schistosoma haematobium for
bladder cancer and Clonorchis sinensis for liver cancer
and bile duct cancer [1]. However, other parasites, such
as Trypanosoma cruzi, Toxoplasma gondii, Toxocara
Canis, and Acanthamoeba castellani, have been sug-
gested to improve the survival of cancer-bearing mice
[2]. Regarding malaria parasites specifically, there are
two opposing viewpoints. In 1981, Greentree proposed
that malaria infection might enhance the host’s immune
system and could serve as an adjuvant to conventional
cancer therapy [3]. In contrast, in 1990, Eze suggested
that malaria infection might trigger the production of
reactive oxygen species or could activate oncogenes and
eventually lead to cancer [4]. One previous study sug-
gested that malaria incidence and all-cancer mortality
might be positively correlated [5]. The author compared
malaria incidence data from 1994 with all-cancer mortal-
ity for the period 1950–1994 in United States. However
the results were limited because the time spans for can-
cer mortality and malaria incidence did not match, and
there were many potential confounders, particularly due
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to variations in economic development and immigration
across the states. In 1994, the entire United States had
fewer than 1000 imported cases of malaria, and it is
known that immigrants usually target more economically
advanced cities. It has been known that a positive correl-
ation exists between malaria infection and the incidence
of Burkitt’s lymphoma (BL) in African children [6, 7].
However, no study has systematically examined the correl-
ation between endemic malaria and the incidences or
mortality rates of other cancers.
Some reports using animal models have suggested a
link between malaria infection and the incidences or
mortality rates of certain cancers. Trager et al. reported
that the plasma of malaria-infected chickens could in-
hibit a chicken Rous I tumor [8]. Contradictory results
have been reported for liver cancer and malaria in rat
models [9, 10]. We recently demonstrated that malaria
infection inhibited tumor growth and metastasis and
prolonged the survival of tumor-bearing mice in a mur-
ine Lewis lung cancer (LLC) model [11]. Plasmodium
yoelii 17XNL (a benign form of a murine malaria para-
site) infection inhibited tumor angiogenesis in mice and
induced innate and adaptive antitumor responses in
LLC-bearing mice, leading to the induction of antitumor
and anti-metastatic activities.
To examine whether such an association also exists in
humans, we systematically analyzed malaria and all-
cause cancer and 29 individual cancer statistical data in




Data regarding malaria cases for the following time periods
were collected from the following sources: 1955–1964,
WHO Epidemiological and Vital Statistics Report (1966);
1962–1981, WHO World Health Statistics Annual (1983);
1982–1997, WHO Weekly Epidemiological Record
(1999); and 1990–2008, WHO 2009 annual report. In
the event of a short overlap between two reports,
data from the later report were used. We compiled
worldwide malaria data from 218 countries for the
period 1955–2008. Worldwide population data for
228 countries during the period 1955–2008 were ob-
tained from the International Database of the U.S.
Census Bureau (http://www.census.gov). The malaria
incidence was calculated by dividing the number of
reported malaria cases by the country’s overall popu-
lation; malaria incidence data were produced for 170
countries in this way.
Cancer data
Age-standardized mortality data on all-cause cancer and
29 individual types of cancer (1955–2008) from 194
countries were obtained from the WHO cancer mortality
database (http://www-dep.iarc.fr/WHOdb/WHOdb.htm);
the database provides statistics separately for each gender.
As shown in Additional file 1: Table S1, merging the
cancer mortality data (1955–2008) with the malaria inci-
dence data provided combined data for 56 countries.
Income information for these 56 countries was obtained
from the World Bank database (http://data.worldbank.org/
country). Data on life expectancies at birth (both sexes
combined) and location data from the 56 countries were
obtained from a publication of the Population Division of
the United Nations Department of Economic and Social
Affairs (World Population Prospects: The 2012 Revision;
http://esa.un.org/wpp/).
Epidemiological data analysis
Using longitudinal malaria incidence and cancer mortal-
ity data from 56 countries, we examined trends in mal-
aria incidence and all-cause cancer mortality for each
country via linear regression. We then applied a gen-
eralized additive mixed model (GAMM) to examine
the association between malaria incidence and cancer
mortality. GAMM has the ability to set a random
intercept to fit a wide range of cancer mortality rates
among countries, to examine the nonlinear relation-
ship between malaria incidence and cancer mortality,
and to adjust for a nonlinear year effect and potential
confounders such as country’s income levels, life ex-
pectancies and geographical locations.
We first examined the distributions of the malaria inci-
dence and cancer mortality rates and then log-transformed
the malaria incidence and cancer mortality rates before
inputting the rates into the models. All the analyses were
performed using Empower software (www.empowerstats.
com, X&Y solutions, Inc., Boston, MA) and R software
(http://www.R-project.org).
Results
Of the 56 countries examined, the data integrity was
different from country to country. The 56 countries
provide average 23-year data, while Venezuela has 50-year
data, but both Barbados and Kuwait have only 6-year data.
Twenty nine countries provide the data of 1955–1981, 9
countries provide the data of 1982–2008, 18 countries
have the data of 1955–2008. Thirty four countries locate
in Asia/Africa/Latin America, among them 3 (Egypt,
Mauritius and South Africa) in Africa, and 22 in Eruope/
North America/Oceania. Twenty five countries were clas-
sified as high-income (high), and 31 were classified as
low- and middle-income (low).
We first drew a smooth curve fitting the malaria inci-
dence and the all-cause cancer mortality. The year 1981
was defined as a turning point; in this year, the malaria
incidence increased, and the all-cause cancer mortality
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decreased significantly. We thus divided the study period
into two periods: 1955–1981 and 1982–2008 in the
following analysis. In addition, 24 countries showed a
significant (P <0.05) increasing trend (up) in malaria
incidence, 8 countries showed a significant decreasing
trend (down) in malaria incidence, and 24 countries
showed a non-significant change over the years (no
change). We summarized the malaria incidence and all-
cause cancer mortality data for the 56 countries from
1955–2008 in Table 1.
Spline smoothing by the GAMM showed a linear inverse
relationship between malaria incidence and all-cause
cancer mortality. A further analysis using the linear
term of malaria incidence showed that a 10-fold in-
crease in malaria incidence was associated with a
lower log-transformed all-cause cancer mortality
(−0.31 [95% CI:-0.37,-0.25], P <0.001, for men and −0.32
[95% CI:-0.37,-0.26], P <0.001, for women; Table 2). After
adjusting for year, life expectancy at birth, income
level, and geographical locations, this negative rela-
tionship persisted (regression coefficients: −0.20 [95%
CI:-0.27,-0.14], P <0.001, for men and −0.20 [95% CI:-
0.25,-0.14], P <0.001, for women). A stratified analysis
showed an inverse relationship between malaria inci-
dence and all-cause cancer mortality regardless of
time periods, national income levels, geographical lo-
cations, or the malaria incidence trend (Table 2).
We then analyzed 29 individual types of cancer, and
found that the inverse relationship between malaria inci-
dence and cancer mortality was significant for colorec-
tum and anus (both men and women), colon (both men
and women), lung (men), stomach (men) and breast
(women) cancer (Table 3). For other individual cancers,
the correlation was not as significant as for these can-
cers. Detailed analyses of other cancer types are given in
Additional file 2: Table S2.
The epidemiological analysis suggested that an inverse
relationship exists between malaria incidence and mortal-
ity due to colorectum and anus, colon, lung, breast and
stomach cancer; however, no significant correlations were
found between malaria incidence and other cancers.
Discussion
In the present study, we utilized WHO cancer and mal-
aria data to conduct longitudinal (1955–2008) analyses
to assess the relationship between these diseases. Our
analyses indicate that endemic or epidemic malaria may
decrease mortality for some solid cancers, including
colon cancer both in men and women, lung and stom-
ach cancer in men, and breast cancer in women.
Country-specific cancer incidence and mortality are as-
sociated with many factors, such as ethnicity, habits,
customs, the level of economic development, the level of
health care, and the level of cancer diagnosis and
treatment. The geographical distribution of the countries
is also a potential confounding factor. Malaria is widely
transmitted in Africa, Asia, and Latin America but
has a low incidence in industrialized countries. An-
other potential confounding factor is the effect of
time. To reduce the effects of these confounding fac-
tors, a GAMM was used to analyze the longitudinal
data. A random intercept effect for each country in
the GAMM regression analysis was used to accommodate
the variations in cancer mortality across different coun-
tries. After adjusting for year, life expectancy at birth, na-
tional income level, and geographical locations, the
inverse relationship between malaria incidence and all-
cause cancer mortality persisted. Recent studies have
demonstrated that some antimalarial drugs, such as
artemisinin and chloroquine, have antitumor activities
[12, 13]; thus, malaria treatment in endemic areas
may affect cancer mortality, as well. However, al-
though artemisinin was only used in clinics after the
1990s [14, 15], our analysis indicated that the negative
relationship between malaria incidence and all-cause
cancer mortality existed before the 1990s, during the
period 1955–1981. Thus, the clinical use of artemisi-
nin should not be a major confounder. Chloroquine
may have been widely used throughout the entire
period 1955–2008, but it was used only for short-
term (3-day) treatment of malaria; thus, it is unlikely
to have significantly affected cancer mortality. Further-
more, our murine Lewis lung cancer (LLC) model studies
have demonstrated that 3-day treatment with a clinically
relevant dose of chloroquine does not improve the sur-
vival of tumor-bearing mice (data not shown). Therefore,
it is less likely that the observed inverse relationship be-
tween malaria incidence and cancer mortality was caused
by the confounding factors discussed above.
Increased levels of economic development and in-
creased life span typically decrease malaria incidence
and increase cancer mortality. Thus, in countries with
low levels of malaria and controlled endemic malaria, an
inverse relationship between malaria incidence and can-
cer mortality would be observed merely through a sim-
ple analysis. To address this issue, we included a year
variable spline smoothing term in the model to control
for this time effect. We also conducted simulation ana-
lyses to estimate class I errors and the statistical power
using data from 8 countries with decreasing malaria in-
cidence. The estimated probability of this finding being
due to chance was <0.035, and the power to detect our
observed effect (−0.03) was 0.752. We also stratified the
countries by trends in malaria incidence (up, down or
no change). Negative correlations between malaria inci-
dence and cancer mortality were observed in each
stratum. Another potential time effect was the changing
population structure over time because aging that relates
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Table 1 Characteristics of malaria incidence and all-cause cancer mortality in 56 countries
Country Period N Malaria incidence All cancers
Male Female
Median (Min-Max) Yr. ratioa Median (Min-Max) Yr. ratio Median (Min-Max) Yr. ratio
Argentina 1966-2008 43 1.80 (0.26-7.08) 0.97 152.62 (132.01-199.59) 0.99 95.59 (86.39-124.56) 0.99
Armenia 1982-2008 22 4.84 (0–37.91) 1.24* 135.54 (115.84-150.75) 1.01 80.115 (69.29-90.5) 1.01
Australia 1955-1981 27 1.29 (0.39-4.30) 1.07* 151.21 (128.66-164.78) 1.01 98.43 (95.23-101.73) 1.00
Austria 1955-1981 26 0.08 (0.01-1.24) 1.15* 189.84 (181.83-199.04) 1.00 128.935 (113.45-138.06) 0.99
Azerbaijan 1982-2007 22 4.7 (0.28-161.40) 1.1 116.3 (77.16-149.99) 0.98 64.825 (47.8-79.77) 0.99
Barbados 1976-1981 6 0.60 (0.40-2.82) 0.75 125.56 (118.13-141.62) 1.01 102.3 (90.87-107) 0.98
Belgium 1955-1981 21 0.05 (0.01-0.60) 1.14* 195.63 (153.64-216.35) 1.01 117.84 (111.95-126.6) 1.00
Belize 1971-1999 21 1505.52 (26.4-4696.7) 1.15* 58.13 (26.39-147.75) 1.02 55.69 (36.51-131.28) 1.01
Brazil 1979-2008 28 281.77 (124.94-404.38) 1.01 93.62 (85.36-103.3) 1.01 67.41 (63.96-72.99001) 1.00
Bulgaria 1964-1981 17 0.15 (0.05-4.74) 1.28* 128.08 (117.99-142.31) 0.99 81.82 (77.03-89.66) 0.99
Canada 1955-1981 24 0.03 (0–2.57) 1.22* 150.21 (134.13-162.86) 1.01 109.23 (104.19-115.47) 1.00
Colombia 1955-2008 39 301.58 (81.42-588.20) 1.01 96.9 (61.78-103.77) 1.01 85.15 (71.38-97.2) 1.00
Costa Rica 1961-2008 47 34.45 (4.54-279.67) 1 103.62 (87.74-124.21) 1.00 88.79 (65.97-100.72) 1.00
Cuba 1970-1981 12 1.29 (0.01-5.90) 1.61* 133.21 (123.91-139.03) 0.99 92.24 (85.03-95.82) 0.99
Denmark 1955-1981 26 0.33 (0.11-2.15) 1.09* 165.54 (151.26-181.88) 1.00 135.72 (125.75-145.28) 1.00
Dominican Republic 1970-2005 31 14.05 (3.15-83.90) 1 42.58 (34.04-61.54) 1.01 39.33 (34.97-51.95) 1.00
Ecuador 1977-2008 29 362.59 (34.07-890.54) 0.98 71.42 (55.09-78.69) 1.00 71.52 (59.06-78.98) 1.00
Egypt 1955-2008 17 0.10 (0.01-474.70) 0.85* 41.35 (22.02-50.13) 1.01 26.23 (13.32-33.14) 1.02
El Salvador 1958-2008 34 147.79 (0.55-1924.15) 0.88* 39.99 (21.8-60.4) 1.02 54.05 (34.52-68.83) 1.01
Finland 1965-1981 15 0.09 (0.02-0.47) 1.16* 184.27 (177.38-195.1) 0.99 98.47 (94.04-106.99) 0.99
France 1955-1981 24 0.04 (0–1.03) 1.14* 185.97 (149.46-207.7) 1.01 100.655 (94.08-106.6) 0.99
Georgia 1990-2007 16 0.43 (0.02-9.25) 1.43* 79.99 (62.51-102.93) 1.00 52.14 (41.88-66.36) 1.00
Greece 1961-1981 21 0.55 (0.30-1.77) 0.96* 125.41 (116.45-145.84) 1.01 75.95 (71.89-82.94) 1.01
Guatemala 1963-2008 25 445.36 (69.81-1004.5) 1.01 67.03 (38.95-78.97) 1.02 75.595 (50.07-84.01) 1.01
Hungary 1955-1981 27 0.06 (0.01-0.46) 0.98 170.12 (130.85-214.48) 1.02 121.71 (114.18-129.34) 1.00
Ireland 1955-1981 17 0.07 (0.03-0.98) 1.13* 158.37 (128.77-169.4) 1.01 121.11 (107.84-130.69) 1.01
Israel 1975-1981 7 0.48 (0.27-1.16) 1.24* 131.36 (118.82-137.7) 0.99 113.88 (107.84-116.67) 0.99
Italy 1955-1981 27 0.07 (0.01-0.43) 1.11* 160.04 (123.09-187.98) 1.02 100.25 (96.73-103.36) 1.00
Japan 1955-1981 27 0.03 (0.01-0.07) 1.03 143.55 (125.39-149.85) 1.00 94.36 (84.6-99.17) 0.99
Kuwait 1975-1981 6 11.93 (7.15-16.04) 0.88* 94.08 (89.14-142.41) 0.95 73.56 (56.31-85.91) 1.02
Kyrgyzstan 1990-2008 19 0.27 (0–54.73) 1.34 103.2 (95.9-139.63) 0.98 66.97 (62.79-79.04) 1.00
Mauritius 1961-1989 29 5.57 (1.26-67.34) 1.08 96.93 (72.36-134.73) 1.01 68.86 (55.38-84.72) 0.99
Mexico 1969-2008 32 22.03 (2.14-174.16) 0.9* 73.52 (51.76-76.71) 1.01 68.87 (64.13-73.67) 1.00
New Zealand 1955-1981 26 0.48 (0.09-2.23) 1.04 157.77 (134.46-175.78) 1.01 114.795 (108.98-124.02) 1.00
Nicaragua 1973-2008 25 524.44 (13.95-1679.01) 0.94 49.55 (15.79-59.14) 1.04 52.13 (21.9-61.56) 1.03
Norway 1955-1981 21 0.08 (0.03-1.39) 1.15* 134.65 (124.81-145.52) 1.01 101.08 (97.48-110.9) 1.00
Panama 1955-2008 47 53.18 (5.81-670.11) 0.96* 73.97 (57.86-91.1) 1.01 66 (55.64-81.41) 1.00
Paraguay 1988-2008 15 21.94 (6.34-187.26) 0.94 72.11 (66.2-74.86) 1.00 63.07 (58.71-65.54) 1.00
Peru 1966-2007 30 179.07 (16.11-984.90) 1.08* 63.9 (40.08-74.8) 1.00 65.13 (38.9-77.01) 1.00
Philippines 1988-2008 15 54.54 (24.62-249.58) 0.91* 92.9 (78.82-100.9) 1.01 65.715 (57.07-71.5) 1.01
Poland 1959-1981 22 0.04 (0.01-0.10) 1.04* 153.43 (103.15-181.65) 1.02 102.625 (81.88-106.09) 1.01
Portugal 1955-1981 27 1.38 (0.04-10.35) 1.05 121.39 (89.41-133.25) 1.01 84.4 (75.34-90.29) 1.00
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to cancer mortality may also relate to malaria incidence.
To address this issue, we stratified the years into two
segments, 1955–1981 and 1982–2008, to narrow the
aging effect. Negative correlations between malaria in-
cidence and cancer mortality were still observed dur-
ing each time period.
There are three limitations to the present study. First,
cancer mortality and malaria incidence data were ob-
tained from WHO publications and databases. Different
countries may use different reporting criteria for the
malaria incidence data. In addition, we were unable to
obtain age-standardized malaria incidence data from
existing databases. For cancer mortality, although the
data were age-standardized for the countries studied,
medical care and cancer reporting systems varied across
countries and may have changed over time; these factors
may affect the comparability of cancer mortality data
between countries and years. Although our analysis
using the GAMM approach maximally accommodated
the limitations of existing data by primarily examining
Table 1 Characteristics of malaria incidence and all-cause cancer mortality in 56 countries (Continued)
Romania 1963-1981 13 0.08 (0.02-0.10) 1.03 127.47 (124.17-131.21) 1.00 86.39 (83.02-98.06) 0.99
Singapore 1963-1981 19 11.53 (7.05-22.80) 0.98 171.88 (157.07-207.55) 1.01 100.32 (91.53-116.34) 1.01
South Africa 1988-2008 17 30.16 (13.08-143.40) 0.97 136.65 (121.25-145.78) 0.99 84.31 (70.13-87.88) 1.01
Spain 1955-1981 27 0.09 (0.02-8.57) 0.94* 134.17 (105.68-151.66) 1.01 86.23 (79.24001-91.09) 1.00
Suriname 1971-2008 26 2058.43 (152.56-14273.09) 1.12* 69.16 (34.15-95.24) 1.00 65.26 (26.55-95.75) 0.99
Sweden 1955-1981 27 0.30 (0.05-1.48) 1.14* 131.41 (117.91-148.03) 1.01 109.24 (101.89-113.42) 1.00
Switzerland 1955-1981 22 0.12 (0.02-2.15) 1.19* 174.17 (169.64-183.12) 1.00 111.08 (102.52-123.75) 0.99
Tajikistan 1982-2005 22 75.25 (3.32-4508.57) 1.46* 71.17 (52.63-110.44) 0.97 52.985 (36.33-69.2) 0.98
Thailand 1959-2006 27 175.6 (41.84-843.59) 0.99 58.68 (13.05-89.11) 1.04 36.42 (10.44-56.02) 1.04
Trinidad and Tobago 1955-1981 8 20.54 (0.27-213.59) 0.8 93.44 (83.49-116.19) 1.00 106.055 (88.44-123.58) 0.99
Turkmenistan 1990-1998 9 0.29 (0.03-3.21) 1.39 102.3 (87.32-132.92) 0.95 66.835 (55.55-81.32) 0.96
United Kingdom 1962-1981 20 0.54 (0–3.65) 1.41* 186.43 (180.55-189.06) 1.00 120.165 (114.59-123.92) 1.00
Uruguay 1963-1978 8 0.04 (0.03-0.15) 0.95 200.58 (192.12-205.04) 1.00 126.605 (119.13-133.04) 0.99
Venezuela 1955-2007 50 66.1 (7.5-249.34) 1.04* 98.74 (89.01-113.05) 1.00 94.185 (77.43-141.76) 0.99
Notes: aYr. ratio: annual change ratio calculated as 10^β, where β is the regression coefficient of the annual log-transformed malaria incidence or cancer
mortalities. *P < 0.05
Table 2 Regression analysis of the relationship between all-cancer mortality and malaria incidence, 1955–2008
Model Male Female
Basic model −0.31 (−0.37, −0.25) *** −0.32 (−0.37, −0.26) ***
Adjusted model −0.20 (−0.27, −0.14) *** −0.20 (−0.26, −0.14) ***
Period
1955-1981 −0.11 (−0.16, −0.05) *** −0.05 (−0.10, 0.00) **
1982-2008 −0.24 (−0.34, −0.15) *** −0.11 (−0.19, −0.03) **
Income
Low −0.28 (−0.37, −0.18) *** −0.25 (−0.34, −0.16) ***
High −0.11 (−0.15, −0.06) *** −0.07 (−0.11, −0.03) ***
Geographical location
Asia/Africa/Latin America −0.27 (−0.36, −0.18) *** −0.24 (−0.33, −0.16) ***
Europe/North America/Oceania −0.16 (−0.20, −0.12) *** −0.10 (−0.13, −0.06) ***
Malaria incidence trend
Down −0.20 (−0.31, −0.08) *** −0.25 (−0.36, −0.13) ***
No change −0.13 (−0.26, 0.00) * −0.06 (−0.18, 0.06)
Up −0.21 (−0.32, −0.10) *** −0.03 (−0.12, 0.07)
Notes
1. Both malaria incidence and cancer mortality data were log transformed. The results shown are 10 times the regression coefficients and 95%
confidence intervals
2. The basic model was adjusted for year; the adjusted model was adjusted for year, life expectancy at birth, national income level and geographical location
3. ***P <0.001; **P <0.01; *P <0.05
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trends over time within each country instead of across
countries, such limitations could not be completely elim-
inated by our data analysis. Second, we do not have
other countries’ data, especially the data from malaria
high endemic countries in Africa. Therefore the impact
of endemic malaria on cancer mortality in our analysis
may mainly reflect vivax malaria that prevails outside
Africa, not falcipuram malaria that prevails in Africa,
even though all four species of human malaria parasite
(Plasmodium vivax, falcipuram, ovale and malariae)
contain pathogen-associated molecular patterns (PAMPs
[16]) that can trigger the antitumor immune response
(see below). Third, the positive relationship between the
incidence of Burkitt’s lymphoma in African children and
falciparum malaria has been well established, because
this malaria causes a prolonged expansion of B cell in
the germinal centers and therefore provides more time
for DNA damage and MYC oncogene translocation that
ultimately leads to Burkitts lymphoma [17], but we were
unable to obtain mortality or incidence data for this
tumor from WHO publications or databases. Thus, our
analysis model lacks information that could be used to
establish a positive relationship between malaria inci-
dence and cancer mortality; such information would be
important for validating our model further.
Malaria infection may serve to enhance immune sur-
veillance mechanisms against some types of solid can-
cers. During the course of malaria, Plasmodium PAMPs
[16] as danger signals are detected by the host immune
cells’ sensors called pattern recognition receptors (PRRs)
which include the toll-like receptors (TLRs) [18] at the
membrane of endosomes or on the cell surface, RIG-I-
like receptors (RLRs) [19] and NOD-like receptors
(NLRs) [20] localized in cytoplasm. The Plasmodium
PAMPs include the known glycosylphosphatidylinositol
anchors (GPI anchors) [21], haemozoin [22] and immu-
nostimulatory nucleic acid motifs [23] and other unknown
molecules [24]. The PRRs activated by Plasmodium
PAMPs trigger distinct transcriptional programs and
stimulate multiple downstream pathways to induce
systemic immune responses [25], including release of
pro-inflammatory and Th1-type cytokines such as
TNF-α, IL-1β, IL-2, IL-6, IL-12, type I and type II IFNs [25,
26], activation of NK cells, NKT cells, γ/δ T cells, macro-
phages and dendritic cells (DCs), afterwards activation of
CD4+ and CD8+ T cells [26, 27] that counteract the tumor
immune-suppressive microenvironment that contains
TGF-β, IL-10, regulatory T cells (Tregs) and myeloid-de-
rived suppressive cells (MDSCs) [28, 29], then turn
the immune-suppressive milieu to immune-supportive
milieu, finally may transform the tumor into an effective
tumor vaccine [30, 31]. On the other hand, malaria
damage-associate molecular patterns (DAMPs), such as
the known intrinsic uric acid, microvesicles and haem
[31–33] also induce similar immune activity. Indeed, our
previous study demonstrated that blood-stage malaria ex-
hibits anti-tumor effects by inducing a potent anti-tumor
innate immune response, including the secretion of IFN-γ
and TNF-α and the activation of NK cells. Our murine
lung cancer model studies also demonstrated that malaria
infection induced adaptive anti-tumor immunity by in-
creasing tumor-specific T-cell proliferation and the
cytolytic activity of CD8+ T cells and increased the
infiltration of these cells into tumor tissues. In these
Table 3 Regression analysis of the relationship between mortality rates associated with 5 individual types of cancer and malaria
incidence, 1955–2008
Cancer Basic model Adjusted model Period
1955-1981 1982-2008
Colon
Male −0.72 (−0.87, −0.56) *** −0.52 (−0.68, −0.36) *** −0.31 (−0.48, −0.14) *** −0.59 (−0.81, −0.38) ***
Female −0.87 (−1.02, −0.72) *** −0.63 (−0.78, −0.48) *** −0.39 (−0.54, −0.24) *** −0.64 (−0.86, −0.43) ***
Colon, rectum and anus
Male −0.51 (−0.62, −0.41) *** −0.37 (−0.47, −0.26) *** −0.25 (−0.37, −0.13) *** −0.41 (−0.58, −0.25) ***
Female −0.58 (−0.68, −0.48) *** −0.42 (−0.52, −0.32) *** −0.34 (−0.46, −0.22) *** −0.45 (−0.60, −0.29) ***
Lung
Male −0.36 (−0.46, −0.25) *** −0.20 (−0.32, −0.09) *** −0.24 (−0.35, −0.12) *** −0.54 (−0.71, −0.37) ***
Breast
Female −0.46 (−0.56, −0.37) *** −0.30 (−0.40, −0.20) *** −0.20 (−0.29, −0.10) *** −0.32 (−0.45, −0.19) ***
Stomach
Male −0.66 (−0.76, −0.55) *** −0.39 (−0.50, −0.28) *** −0.31 (−0.40, −0.21) *** −0.23 (−0.37, −0.08) ***
Notes
1. Both malaria incidence and cancer mortality data were log transformed. The results are 10 times the regression coefficients and the 95% confidence intervals
2. The basic model was adjusted for year; the adjusted model was adjusted for year, life expectancy at birth, national income level and geographical location
3. ***P <0.001
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studies, we found that in approximately 10% of lung
cancer (LLC)-bearing mice infected with malaria para-
site, the tumor regressed and did not regrow when
the mice were re-inoculated with the same cancer
cells, most likely because of the long-term memory of
specific antitumor cellular immunity [11]. Study by
Deng XF and colleagues demonstrated that attenuated
liver-stage Plasmodium inoculation induced antitumor
innate immune response, including secretion of TNF-
α, IL-6/12 and IFN-γ and antitumor adaptive immun-
ity with increasing cytolytic activity of CD8+ T cells
[34]. Our unpublished data suggest that blood-stage
Plasmodium infection significantly decreases the
numbers of MDSCs in breast cancer (4 T1)-bearing
mice or Tregs in lung cancer (LLC)-bearing mice. In
addition, our previous study indicated that malaria
infection significantly inhibited tumor angiogenesis in
mice [11]. A review by Hobohm [35] suggested that
the fever induced by malaria infection may cause an
increase in tumor cell death. Based on our previous
study and our unpublished data, parasitemia is
required to effectively inhibit tumor growth. However,
in mice, Plasmodium infection causes only a short-
term infection without fever. Repeated Plasmodium
infection is difficult to observe in murine models
[36]. In humans lacking effective antimalarial treat-
ment, Plasmodium infection can cause long-term
parasitemia that is accompanied by a high fever in
the acute phase, and this syndrome can recur many
times throughout the life span [37]. Therefore, a naturally
acquired Plasmodium infection by mosquito bite would
produce liver-stage and blood-stage malaria that sequen-
tially stimulate the immune systems to turn the tumor
into the effective tumor vaccine, in combination with fever
during the acute phase and the inhibition of tumor angio-
genesis. In medical literature, febrile infection was linked
to spontaneous regression of tumor [38], and malaria is
a typical febrile infection. Other pathogen infections
may have similar impact on cancer mortality or morbidity
[39, 40], due to a similar mechanism of PAMPs-triggered
antitumor immunity [41], but malaria parasite may be
more significant than other pathogens, because malaria
contains two stages (liver and blood) of infection, mani-
fests typical high fever paroxysms during acute phase and
may last longer period if not treated with effective anti-
malarial drugs. In addition, malaria is a well-documentary
infectious disease in WHO databases and publications
partially due to easily to be diagnosed by fever paroxysm
and a simple blood smear test. Other pathogen infections
lack well-documentary data in WHO databases or publi-
cations for analysis. In summary, some or all of these
above mentioned factors and mechanisms may explain
why endemic malaria might reduce cancer mortality
at the population level.
Conclusion
We report an inverse association between malaria inci-
dence and the mortality rates of all-cause and several
types of solid cancers. However, because this study is a
descriptive retrospective analysis, we are unable to draw
a causal relationship between malaria and the mortality
rates of some cancers. More well-defined prospective
epidemiological studies are required to confirm this rela-
tionship. We recommend that public health officials in
the WHO and in individual countries coordinate malaria
control programs and cancer epidemiological studies in
the future. In addition, more comprehensive mechanistic
studies should be conducted.
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